【Native Speaker每日综合训练—38系列】【38-07】科技 Stem Cells

daisyjin

speaker:
Stem cells can defend the muscle damaged.
It refers that injecting stem cells makes people fight stronger than the one without injecting.
However, it's too early to conclude the stem cells can make life longer.

2:
The stem cells are valuable.
However, they are too naive and risky.
We do not know whose IP come across now. We lack the basic experiment.
It's too risky to build such a company now.

3:
We must notice the risk before using the stem cells.
Such business in europe is difficult, while the critism provides the Austrilia a good envionment to do the reserach.
People's expectation about stem cells is more enormous than the one actually holds.

4:
Stem cells foundation is builded.

5:
Government is rising the budget on stem cells.
However, the situation is not better in europe.
The companies doing this is fragmental.

6:
A company cannot be built with only one product.
The stem cells are tainted.
The proposition 71 is aimed to change the position of stem cells.

obstacle:
NIH prohibits the research on cells taken from embryos created solely for research and CRIM.
Some scientists says that the defend is overestimated.
NIH does profibit the using of cells but not the making of cells.
CRIM is also aimed to change its regulation.

bejamin1111

【1】1分8秒；
studies show that stem cells help to cure heart attacks
【2】2分49秒；
VC is caucious about funding stem cell companies because the science is too preliminary and the business plan is too risky;
【3】2分50秒；
VC in different countries. lots of stems cell startups go public in Austrilia. VC invest in these startups at different stages to lower risk. people's expectation is beyond actual science research.
【4】1分30秒；
Money is needed to narrow the gap between acdemic research and clinical trials. the future is promosing;
【5】1分23秒；
the main issue for stems cell trial to go to market is the regulatory side. the market for it is fragmented due to different regulations in different countries.
【6】43秒；
ethical and regulatory factors are big concerns.
【obstacle】4分19秒；
strict regulations make stems cell research hard to progress.

huwanyue123

Day66
38－07
Speed
Time2
VC Company is cautious in investing in stem cell investigation programs for it thinks it is unattractive because of the high risk.
Time3
The stem cell program companies are always focus on one part and the industry lacks a platform. Then the Australia has a special form, having attract many money
Time4
To solve the problems mentioned before, a man decided to make a foundation, a charity designed to plug the gap between academic research and mid-stage clinical trials.
Time5
Though the government has support such as budget for it, the stem call system faces problem like difference regulation. And the market fragmentation is making stem cells a very, very difficult business model for big pharm
Time6
It’s reasonable for the VC to be careful.

Obstacle
1 停止:00:02:11.191        
2 停止:00:03:41.112        
3 停止:00:02:23.263        
4 停止:00:01:49.063        
5 停止:00:01:06.743        
6 停止:00:04:13.100        

crazylucia

day1
speed:
2) 1'51''
3) 2'01''
4) 1'02''
5) 0'54''
6) 0'33''

viennall

Speaker
Stem cells may be regarded as a quick fix for damaged heart tissue. The heart disease patients with stem cell therapy have stronger stickers for years to come than patients who are not treated with stem cell.

Speed
03'30 VC invested much less many to stem cells than other technology. Not only is the science too preliminary, but the business plans are to risky.
03'18 Stem cells have not been developed as a platform and too many companies are focusing on a single treatment for specific disease. The VC for stem cells in Europe may encounter obstacles, but have oppotunies in Australia and Sinapore.
02'09 Evan formed the Stem Cell Foundation to plug the gap between acadamic research and mid-stage clinical trials, which may attract more investment in stem cells.
01'54 It is unclear whether it will be possible to get a single regulatory approval to sell a stem cell therapy across the US. The market fragmentation makes stem cells very difficult model for big pharma.
00'49 VCs are dounted by the ethical and regulatory baggage surrounding stem cells.

obstacle
04'53

Main idea: The restrictions of new stell cell lines.
Structure:
The annoucement of the creation of stem cells lines from a cloned human embryo is a breakthrough in stem cell research.
But the research needs to be done under the US NIH regulatory lines.
The CIRM forbid paying the donors money for the eggs.
It is too difficult to receive the new stem cell lines within the rules of both NIH and CIRM.
Most labs will continue working with current stem cell lines due to the restrictions of NIH.
Some scientists think the restricions of NIH are overestimated.
CIRM is re-examing the rules. It does not likely alter the restrictions against the studies that pay cell donors. But other rules which will be overturn need much long time.

happyxgb

Time 2: 02:40
Time 3: 02:52
Time 4: 01:20
Time 5: 01:09
Time 6: 00:43
Obstacle: 05:14
Restrictions on stem cells: eggs of donors are forbidden & only performed in private laboratories.  
The change raises concerns: questions limited and insufficient analysis
But some thinks that impacts of stem cells are overestimated.
CIRM are re-examing the rules that governs the research it supports

happyxgb

Time 2: 02:40
Time 3: 02:52
Time 4: 01:20
Time 5: 01:09
Time 6: 00:43
Obstacle: 05:14
Restrictions on stem cells: eggs of donors are forbidden & only performed in private laboratories.  
The change raises concerns: questions limited and insufficient analysis
But some thinks that impacts of stem cells are overestimated.
CIRM are re-examing the rules that governs the research it supports

NativeStudy菌

vicnan 发表于 2014-6-23 23:10
mark!就占位好犀利

Hey, vicnan~
Note that you've taken the first page seat, and it requires you to finish reading the passage in 3 days, otherwise, your message will be deleted~
Have a nice day!

leo688

[Time 2/3/4/5/6]
2'50 2'10 1'30 1'40 1'

It took +20 yrs from research to marked for anibodies.

VCs face risky
lack of funding
ex Austrila stock list too early
no clinical trials
no single relatory approval
how to control the risk is sophisticated

Part III: Obstacle
6'20
Restrictions on stem cell research.
selected research for stem cell
restriction in US
overestimated the limitations

SukeyZhou

20160621
【38-07】科技 Stem Cells
【Time 2】
It’s hard for venture capitalists to invest in stem cells, because the science is too preliminary and the business plans are too risky.

【Time 3】
The author talks about how various companies around the world have a trial to invest in stem cells. And only a few companies survives.

【Time 4】
It’s about a trial to bridge the gap between academic study and clinical trials.

【Time 5】
Here is another obstacle: regulatory side of different countries, which makes a cell stem therapy a fragmented marketplace.

【Time 6】
Since there are many obstacles for the business of cell stems, the businesses have to be more sophisticated towards risk. And the author believes that this kind of business is investible.

【Paraphrase 7】
The author talks about the regulation on the experiments and research of cell stems.


Time 2  00:03:09
Time 3  00:03:30
Time 4  00:01:26
Time 5  00:01:22
Time 6  00:00:53
Paraphrase 7  00:05:15